
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is a leading player in the genomics space, with a strong focus on rare and ultra-rare pediatric disorders. The company's exome and genome sequencing technology has the potential to revolutionize healthcare by allowing for proactive genetic testing and earlier diagnosis for patients. While the company has faced some challenges in its revenue guidance and execution, its ongoing investment in sales force and continued focus on exome and genome testing should drive growth and improved financial performance in the long term.
Bears say
GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services, but its Q1 results missed expectations, with a weaker outlook for full-year revenue and volume growth. The company is facing headwinds from mix and softness in non-core businesses, and there are risks related to the adoption of whole exome and whole genome tests and the slow growth of the rare disease market. Despite its potential and strong industry positioning, GeneDx will likely face challenges in the short term and its stock has a negative outlook for now.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares